Scientific Zambon Pharma 10 Aprile 2017 ZAMBON LAUNCHES XADAGO® (SAFINAMIDE) IN PORTUGAL FOR PATIENTS WITH MID- TO LATE-STAGE PARKINSON’S DISEASE
Scientific Zambon Pharma 21 Marzo 2017 FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON’S DISEASE (PD) PATIENTS
Institutional Zambon Pharma 10 Gennaio 2017 Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand
Institutional Zambon Pharma 2 Novembre 2016 Agreement Zambon - Fabbrica Italiana Sintetici (FIS) for the development of the Lonigo plant
Scientific Zambon Pharma 1 Settembre 2016 Zambon launches Xadago® (safinamide) in Norway for patients with mid- to late-stage Parkinson's disease
Scientific Zambon Pharma 6 Luglio 2016 Zambon lauches Xadago® (safinamide) in the Netherlands for patients with mid-to-late-stage Parkinson’s Disease
